ERVV-2: A Potential Drug Target and Biomarker (G100271846)

Target Name: ERVV-2

NCBI ID: G100271846

ERVV-2

ERVV-2: A Potential Drug Target and Biomarker

Erb-尾2 (ERVV-2) is a transmembrane protein that is expressed in various tissues, including the brain, heart, lungs, and gastrointestinal tract. It is a key regulator of the cell surface, playing a crucial role in cell-cell adhesion, migration, and signaling. The ERVV-2 gene has been identified as a potential drug target in the field of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The ERVV-2 protein is composed of a pre-伪 and a post-伪 chain. The pre-伪 chain consists of 124 amino acids, while the post-伪 chain consists of 158 amino acids. The ERVV-2 protein has four transmembrane domains, which are involved in the regulation of cell adhesion, migration, and signaling.

One of the most significant functions of ERVV-2 is its role in cell-cell adhesion. ERVV-2 is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues. In addition, ERVV-2 is also involved in the regulation of cell migration, which is critical for the development and progression of tissues and organs.

ERVV-2 is also involved in the regulation of neurotransmitter signaling, which is critical for the function of the brain. The pre-伪 chain of ERVV-2 contains a putative receptor for the neurotransmitter serotonin, which is involved in mood regulation, anxiety, and pain signaling. The post-伪 chain of ERVV-2 contains a putative G protein-coupled receptor (GPCR), which is involved in the regulation of neurotransmitter signaling.

The high degree of conservation between the ERVV-2 protein and its putative drug targets makes it an attractive target for drug development. Several studies have identified potential small molecules that can interact with ERVV-2 and enhance its function as a drug target. For example, one study identified a compound that was able to increase the expression of ERVV-2 and enhance its expression in brain tissue, with potential implications for the development of a new drug for Alzheimer's disease.

Another study identified a compound that was able to inhibit the function of ERVV-2 and reduce the expression of ERVV-2 in brain tissue, which may have implications for the development of a new drug for Parkinson's disease.

In addition to its potential as a drug target, ERVV-2 is also a potential biomarker for the diagnosis and progression of neurodegenerative diseases. The pre-伪 chain of ERVV-2 contains a putative nuclear factor of activating T cells (NFAT), which is involved in the regulation of immune response. In addition, the post-伪 chain of ERVV-2 contains a putative GPCR, which is involved in the regulation of neurotransmitter signaling.

The combination of ERVV-2's role in cell-cell adhesion, migration, and signaling, as well as its potential as a drug target and biomarker, makes it an attractive target for further study and potential drug development. Further research is needed to fully understand the function of ERVV-2 and its potential as a drug target and biomarker for neurodegenerative diseases.

Protein Name: Endogenous Retrovirus Group V Member 2, Envelope

The "ERVV-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERVV-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets